Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

January 26, 2017
Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in addition to fast track status. Zilretta is an extended release formulation of the triamcinolone acetonide. Steroid injection is a common treatment, but pain relief wanes after two to four weeks. Competing against generic steroids, which cost only USD 10–20 per dose, presents a big commercial challenge however. In an interview at Biotech Showcase, Clayman explains the rationale for pricing a long-acting steroid at USD 500 per dose and the company's commercial strategy.
Previous Article
UK Establishment upbeat about Brexit’s effect on British life science industry
UK Establishment upbeat about Brexit’s effect on British life science industry

Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma comp...

Next Article
Finding the value of real-world evidence
Finding the value of real-world evidence

Real-world evidence isn’t about what happens in the clinic, but is just as important to your success. It’s ...